Global and Chinese Stem Cell Industry Report, 2015-2018

Description: Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hundreds of diseases in clinical studies, of which about 50% is applied to blood diseases. In addition to blood diseases, tumors, neurological system diseases, heart disease, immune system diseases and the like are also important fields of stem cell clinical research.

Up to now, only 12 sorts of stem cell products have been approved for marketing after rigorous safety and effectiveness review worldwide. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. allowance funds) and the capital support of key partners, very few companies have dropped out.

Considerable stem cell therapy products are in clinical trials worldwide. For example, the United States National Institutes of Health (NIH) had registered 4,293 cord blood-related clinical research projects as of December 23, 2014 and 5,190 ones as of November 17, 2015, including 484 ones in East Asia.

Restricted by policies, capital, technology and other factors, China's stem cell therapy develops slowly. At present, China has not approved any stem cell drug product for marketing. As for stem cell research, Chinese authorities have not accepted or reviewed any stem cell therapy of any medical institution except hematopoietic stem cells suitable for treating blood diseases; besides, the stem cell clinical applications of some hospitals pertain to the scope of pilot clinical studies.

In February 2015, Ministry of Science and Technology of the People's Republic of China published the Stem Cell and Translational Medicine Implementation Plan of National Key R&D Program (Draft). In August 2015, CFDA (China Food and Drug Administration) issued Management on Clinical Stem Cell Experimental Study (Trial). With the relaxation of policies, the stem cell industry has attracted Chinese investors once again.

On December 4, 2014, Xi'an International Medical Investment (formerly known as Kaiyuan Investment) announced to invest RMB270 million in acquiring 34% stake in H & B's registered capital in order to accelerate the development of health care services and foster new profit engines.

On April 17, 2015, Yinhe Investment proclaimed that it would associate with its controlling shareholder Yinhe Group to jointly lavish RMB2 billion in the establishment of Biomedical M&A Fund whose total size hits RMB6 billion. The fund is mainly used for immunotherapy, stem cell clinical application platforms, macromolecular drugs, antibody drug development and other fields.

On October 27, 2015, Ningxia Xinri Hengli Steel Wire Rope Co., Ltd. released a restructuring plan to take over 80% stake in BoyaLife from Xu Xiaochun, , Maoxing Investment Management (Hangzhou), Yang Lijuan , Wang Jianrong, etc. with RMB1.5656 billion.

Global and China Stem Cell Industry Report, 2015-2018 highlights the followings:

Classification, application, industry chain definition, etc. of stem cells; Major enterprises, policies, upstream/midstream/downstream development and prospects, etc. of global stem cell industry; Policies, upstream/midstream/downstream development, etc. of China stem cell industry; Operation, stem cell business, etc. of 8 upstream companies and 20 midstream/downstream companies worldwide.

Contents: 1. Overview of Stem Cell Industry
1.1 Definition
1.2 Classification and Application
1.3 Industry Chain
1.4 Development Course
5.2.1 Profile
5.2.2 Operation
5.2.3 R&D and Investment
5.2.4 Stem Cell Business
5.3 MEDIPOST
5.3.1 Profile
5.3.2 Operation
5.3.3 Stem Cell Business
5.4 Beike Biotechnology
5.4.1 Profile
5.4.2 Stem Cell Business
5.5 Osiris Therapeutics
5.5.1 Profile
5.5.2 Operation
5.5.3 R&D
5.6 Orthofix International
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 R&D
5.6.5 Stem Cell Business
5.7 Cytori Therapeutics
5.7.1 Profile
5.7.2 Operation
5.7.3 R&D
5.8 Athersys
5.8.1 Profile
5.8.2 Operation
5.8.3 R&D
5.9 Pluristem Therapeutics
5.9.1 Profile
5.9.2 R&D and Recent News
5.10 StemCells
5.10.1 Profile
5.10.2 Operation
5.10.3 R&D
5.11 Ocata
5.11.1 Profile
5.11.2 Operation
5.11.3 R&D
5.12 Celgene
5.12.1 Profile
5.12.2 Operation
5.12.3 R&D
5.13 Vitro Biopharma
5.13.1 Profile
5.13.2 Operation
5.13.3 R&D
5.13.4 Stem Cell Business
5.14 Reneuron
5.14.1 Profile
5.14.2 Operation
5.14.3 R&D
5.15 Tigenix
5.15.1 Profile
5.15.2 Operation
5.15.3 R&D
5.16 Cellular Biomedicine
5.16.1 Profile
5.16.2 Operation
5.16.3 R&D
5.16.4 Stem Cell Business
5.16.5 Business in China
5.17 SALIAI
5.17.1 Profile
5.17.2 Operation
5.17.3 Stem Cell Business
5.18 Opexa Therapeutics
5.19 ZhongKe Biopharm
5.20 Cyagen Biosciences

Selected Charts

Classification of Stem Cell
Overview of Stem Cell Therapy Area (by Disease Type)
Advantages and Disadvantages of Stem Cell Therapy
Source and Application of Adult Stem Cells (by Type)
Stem Cell Industry Chain
Industry Chain Distribution of Major Global Stem Cell Enterprises
Policy Tendency of Human Embryonic Stem Cell Research Worldwide
Stem Cell Products Granted “Orphan Drug” by EU EMEA
Global Authorized Stem Cell Varieties
Top 20 Indications of Global In-research Stem Cell by the end of 2014
Global Stem Cell Products in Late R&D Stage
Global Stem Cell Market Size and YoY Growth, 2007-2014
Global Human Stem Cell Clinical Trials and Treatment Application Structure, 2014
Clinical Application of Global Stem Cell Technology (by Disease Type), 2014
Cord Blood Bank Distribution in Major Countries by the end of 2014
Cord Blood Application in Major Countries
Global Top 10 Death Causes (by Death Toll), 2012
Global Top 10 Death Causes (by Income Group), 2012
Global Top 10 Death Causes in Low-income Countries, 2012
Global Top 10 Death Causes in Low- and Middle-income Countries, 2012
Global Top 10 Death Causes in Middle- and High-income Countries, 2012
Global Top 10 Death Causes in High-income Countries, 2012
Application Prospect of Global Stem Cell
Global Stem Cell Market Size and YoY Growth, 2014-2018E
Some Chinese Stem Cell Clinical Trial Drugs Approved by CFDA
Construction of Chinese Stem Cell Industrialization Bases
Major Enterprises and Their Stem Cell Business in China Upstream Stem Cell Industry
Major Enterprises and Their Stem Cell Business in China Midstream Stem Cell Industry
Total Assets, Total Liabilities and Asset-liability Ratio of Cryo-Cell International, FY2010-FY2014
Cord Blood Revenue and % of Total Revenue of Cryo-Cell International, FY2012-FY2015
Revenue and Net Income of Esperite, 2010-2015
Revenue of Esperite (by Business), 2010-2015
Revenue Structure of Esperite (by Region), 2014
Stem Cell Storage of Esperite, 2009-2014
Stem Cell Storage Revenue and EBITA of Esperite, 2010-2015
Operation of Main Subsidiaries of VCANBIO by 2015H1
Revenue and Net Income of VCANBIO, 2010-2015
Revenue of VCANBIO (by Business), 2011-2015
Revenue of VCANBIO (by Region), 2011-2015
Gross Margin of VCANBIO (by Business), 2011-2015
R&D Costs and % of Total Revenue of VCANBIO, 2011-2015
Fund-raising Investment Projects and Progress of VCANBIO, by Jun 30, 2015
Stem Cell Storage Business of VCANBIO (by Type), 2009-2014
Revenue and Net Income of VCANBIO, 2014-2017E
Revenue and Net Income of Golden Meditech, FY2009-FY2014
Revenue of Golden Meditech (by Business), FY2009-FY2014
Cord Blood Bank Revenue and % of Total Revenue of Golden Meditech, FY2011-FY2014
Development Course of Golden Meditech's Cord Blood Storage Business
Revenue and Net Income of Golden Meditech, FY2014-FY2018E
Development Course of LifeCell International
Revenue and Net Income of Cryosite, FY2011-FY2015
Revenue and EBITDA of Cryosite (by Business), FY2011-FY2014
Equity Structure of Health & Biotech
Industry Base Distribution of Health & Biotech
Revenue and Net Income of Health & Biotech, 2012-2014
Revenue and Net Income of Tian Qing Stem Cell, 2013-2015
Revenue (by Business) of Tian Qing Stem Cell, 2013-2015
Subsidiaries of Caladrius Biosciences, by the end of 2014
Revenue and Net Income of Caladrius Biosciences, 2009-2015
Revenue (by Business) of Caladrius Biosciences, 2012-2015
R&D Costs and % of Total Revenue of Caladrius Biosciences, 2009-2014
M & A Course of Caladrius Biosciences, 2009-2014
Revenue and Net Income of Mesoblast, FY2009-FY2015
R&D Costs and % of Total Revenue of Mesoblast, FY2009-FY2015
M&A Course of Mesoblast by the end of 2014
Stem Cell Product R&D Progress of Mesoblast by the end of June 2015
Revenue and Net Income of MEDIPOST, 2011-2014
Adult Stem Cell Drugs and Therapeutic Area of MEDIPOST
Development Course of Beike Biotechnology
Stem Cell Brands and Therapeutic Area of Osiris Therapeutics
R&D Costs and % of Total Revenue of Osiris Therapeutics, 2011-2015
Revenue of Orthofix International (by Department), 2011-2015
R&D Costs and % of Total Revenue of Orthofix International, 2011-2015
Revenue, Net Income and Gross Margin of Cytori Therapeutics, 2010-2015
Revenue of Cytori Therapeutics (by Region), 2010-2015
R&D Costs and % of Total Revenue of Cytori Therapeutics, 2010-2015 Revenue and Net Income of Athersys, 2010-2015
Revenue of Athersys (by Source), 2010-2015
R&D Costs and % of Total Revenue of Athersys, 2010-2015
Significant Cooperative Partners and Areas of Athersys
Revenue and Net Income of StemCells, 2011-2015
R&D Costs and % of Total Revenue of StemCells, 2011-2015
Stem Cell Product R&D, Therapeutic Area and Progress of StemCells by 2015H1
Revenue, Net Income and Gross Margin of Ocata, 2010-2015
R&D Costs and % of Total Revenue of Ocata, 2010-2015
Stem Cell Product R&D, Therapeutic Area and Progress of Ocata by the end of 2014
Revenue, Net Income and Operating Margin of Celgene, 2009-2014
Cellular Therapy R&D Costs and % of Total Revenue of Celgene, 2009-2013
Stem Cell Products R&D, Therapeutic Area and Progress of Celgene as of 2014H1
Revenue and Net Income of Vitro Biopharma, FY2009-FY2015
R&D Costs and % of Total Revenue of Vitro Biopharmas, FY2009-FY2015
Stem Cell Brands and Application Fields of Vitro Biopharma
Revenue and Net Income of Reneuron, FY2010-FY2015
R&D Costs and % of Total Revenue of Reneuron, FY2010-FY2015
Stem Cell Products R&D, Therapeutic Area and Progress of Reneuron by the end of 2014
Revenue and Net Income of Tigenix, 2009-2015
Sales of Tigenix (by Region), 2011-2013
R&D Costs and % of Total Revenue of Tigenix, 2012-2015
Stem Cell Product R&D, Therapeutic Area and Progress of Tigenix by 2015H1
Development Course of Cellular Biomedicine
R&D Costs and % of Total Revenue of Cellular Biomedicine, 2013-2015
Stem Cell Product R&D, Therapeutic Area and Progress of Cellular Biomedicine by 2015H1
Revenue and Net Income of SALIAI, 2013-2015

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global and Chinese Stem Cell Industry Report, 2015-2018
Web Address: http://www.researchandmarkets.com/reports/3501258/
Office Code: SCH36YR3

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>☐ USD 2400</td>
<td></td>
</tr>
<tr>
<td>Hard Copy</td>
<td>☐ USD 2600 + USD 58 Shipping/Handling</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>☐ USD 3800</td>
<td></td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ________________________________ Last Name: ________________________________
Email Address: *
Job Title: ________________________________
Organisation: ________________________________
Address: ________________________________
City: ________________________________
Postal / Zip Code: ________________________________
Country: ________________________________
Phone Number: ________________________________
Fax Number: ________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:

Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World